Is PT-141 (Bremelanotide) Legal in North Carolina? How to Access It Legally
HealthRX.com
Bremelanotide is legal only as a prescription medicine, Vyleesi
Key numbers
- 1.75 mgVyleesi's labeled dose: a prescription-only autoinjector for premenopausal women with HSDDSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 45 minutesTiming: inject at least this long before anticipated sexual activity, per the labeled dose of 1.75 mgSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 8 weeksTreatment should stop if HSDD symptoms have not improved after this longSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 40%Share of Vyleesi patients who reported nausea, versus about 1% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Bremelanotide
At a glance
- Drug / Bremelanotide, FDA-approved as Vyleesi
- Approval / June 21, 2019, NDA 210557 [1][2]
- Approved use / Acquired, generalized HSDD in premenopausal women [1]
- Prescription status / Prescription only; no boxed warning, no REMS [1][2]
- Dose and route / 1.75 mg subcutaneous autoinjector, as needed [1]
- Compounded or research PT-141 / Not Vyleesi; not an FDA-approved drug [1][3]
- FDA bulk-substance lists / Bremelanotide appears in no category [4][5]
What the federal status is
Bremelanotide is a prescription medicine, approved by FDA on June 21, 2019 as Vyleesi, a 1.75 mg prefilled autoinjector now held by Cosette Pharmaceuticals. The label has no boxed warning, and no risk evaluation and mitigation strategy (REMS) appears in the label or the 2019 approval letter [1][2].
The approved use is narrow: premenopausal women with acquired, generalized HSDD, meaning low sexual desire causing marked distress or interpersonal difficulty that is not due to a co-existing medical or psychiatric condition, relationship problems, or a medication or drug. Acquired means it developed in a woman who previously had no such problem; generalized means it occurs regardless of stimulation, situation or partner. The label says it is not indicated for HSDD in postmenopausal women or in men, and not to enhance sexual performance [1].
The labeled dose is 1.75 mg injected subcutaneously into the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity. The label says not to give more than one dose in 24 hours, that more than 8 doses a month is not recommended, and that treatment should stop if symptoms have not improved after 8 weeks [1].
The PT-141 sold online is a different product
Vyleesi is the FDA-approved bremelanotide product. Anything sold as compounded or research-use PT-141 is not Vyleesi and is not an FDA-approved drug, and compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [1][3].
Bremelanotide appears in no category on FDA's bulk-substance lists for compounding, including the list of substances that may present significant safety risks (content dated 04/22/2026) [4][5]. It is also not one of the six peptides named in HHS's October 2026 draft enforcement-discretion policy [6].
How legal access works
Vyleesi is a prescription product. The label describes it as self-administered with a prefilled autoinjector pen [1].
Questions worth asking
What the label warns about
The label lists uncontrolled hypertension and known cardiovascular disease as contraindications. Each dose raises blood pressure transiently: maximal increases of 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after dosing, with heart rate down by up to 5 beats per minute and a return to baseline usually within 12 hours [1]. In an open-label study of 127 premenopausal women dosed daily for 8 days, mean daytime blood pressure rose 1.9 mmHg systolic and 1.7 mmHg diastolic [1].
Nausea was reported by 40% of patients on Vyleesi versus about 1% on placebo; 13% took an anti-nausea medicine and 8% stopped the trials over it [1]. Focal hyperpigmentation (darkening of skin, gums or breasts) occurred in 1% of patients taking up to 8 doses a month versus none on placebo. It was more likely in darker skin and with daily dosing, and resolution was not confirmed in all patients after stopping treatment [1]. The label also says to avoid Vyleesi with oral naltrexone products intended to treat alcohol or opioid addiction, because Vyleesi may significantly decrease naltrexone exposure [1].
Frequently asked questions
Is PT-141 legal in North Carolina?
Do I need a prescription to get bremelanotide?
Can I buy PT-141 online without a prescription?
Can a compounding pharmacy make bremelanotide?
Is Vyleesi approved for men?
What is the approved dose?
References
Show all 7 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- U.S. Food and Drug Administration.
- Official web page.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- Official web page.
- Import Alert 66-41.